According to Haoyuan Pharmaceutical's announcement, the company will issue convertible bonds to unspecified targets in 2024, raising a net capital of 812 million yuan. In order to improve the efficiency of the use of funds, without affecting the progress of the fund-raising project and the normal operation of the company, it is proposed to use no more than 500 million yuan of idle raised capital for cash management and purchase capital protected investment products. The period of use is valid for 12 months from December 12, 2025, and the funds can be used on a rolling basis. Previously, due to staff mistakes, the authorized amount of 49 million yuan was exceeded for cash management, and the excess products have now been redeemed. The matter has been approved by the board of directors, there is no need to submit it to the shareholders' meeting for consideration, and there is no objection from the sponsor.

According to Haoyuan Pharmaceutical's announcement, the company will issue convertible bonds to unspecified targets in 2024, raising a net capital of 812 million yuan. In order to improve the efficiency of the use of funds, without affecting the progress of the fund-raising project and the normal operation of the company, it is proposed to use no more than 500 million yuan of idle raised capital for cash management and purchase capital protected investment products. The period of use is valid for 12 months from December 12, 2025, and the funds can be used on a rolling basis. Previously, due to staff mistakes, the authorized amount of 49 million yuan was exceeded for cash management, and the excess products have now been redeemed. The matter has been approved by the board of directors, there is no need to submit it to the shareholders' meeting for consideration, and there is no objection from the sponsor.